The present invention relates to the use of an extract of Zingiber zerumbet, in particular of Zingiber zerumbet rhizome, or of a dermatological or cosmetic composition comprising such an extract, for combating dandruff and/or preventing the formation thereof.

A hydrocarbon oil intended to be used as a drug including a content by weight of isoparaffins ranging from 90 to 100%, a content by weight of normal paraffins ranging from 0 to 10% and having a content of carbon of biological origin greater than or equal to 90% relative to the total weight of the hydrocarbon oil.

A hydrocarbon oil intended to be used as a drug including a content by weight of isoparaffins ranging from 90 to 100%, a content by weight of normal paraffins ranging from 0 to 10% and having a content of carbon of biological origin greater than or equal to 90% relative to the total weight of the hydrocarbon oil.

The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

The present invention relates to methods for treating dermatitis and the use of a β-1 adrenoceptor antagonist in manufacturing a pharmaceutical composition for treating dermatitis. The methods comprise the step of administering the pharmaceutical composition comprising a therapeutically effective amount of β-1 adrenoceptor antagonist to a subject in need thereof.

The present invention relates to methods for treating dermatitis and the use of a β-1 adrenoceptor antagonist in manufacturing a pharmaceutical composition for treating dermatitis. The methods comprise the step of administering the pharmaceutical composition comprising a therapeutically effective amount of β-1 adrenoceptor antagonist to a subject in need thereof.

The present disclosure provides methods for treating or alleviating symptoms of a disease, disorder, or condition related to excess androgen or stress-induced skin changes in a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Other aspects relate to methods for providing anti-oxidative stress, anti-inflammatory and anti-aging benefits for the skin to a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Surprisingly, it has been found that spironolactone may be topically administered with reduced adverse effect compared to systemic administration of the same medication.

The present disclosure provides methods for treating or alleviating symptoms of a disease, disorder, or condition related to excess androgen or stress-induced skin changes in a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Other aspects relate to methods for providing anti-oxidative stress, anti-inflammatory and anti-aging benefits for the skin to a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Surprisingly, it has been found that spironolactone may be topically administered with reduced adverse effect compared to systemic administration of the same medication.

Topically administrable compositions and methods are included for treating inflammatory skin disease in mammals. The composition includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more of these, and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination of these. The composition further includes a therapeutic amount of topical corticosteroid. The combination of non-sedating antihistamine and corticosteroid with emu oil has been found to produce a synergistic effect that is more effective in the treatment of inflammatory skin disease than the compounds used separately.

The invention relates to a new bacterial extract that can be used for protecting and/or treating sensitive skin and/or reactive, intolerant skin, particularly by means of targeted action on neurogenic inflammation of the skin. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial extract as an active ingredient.